# Tricida

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tricida

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.tricida.com/
- Total disclosed funding: $109M
- Latest round: Series D (Nov 8, 2017)
- Investors on record: 8

## About

Tricida, Inc. is a US-based biopharmaceutical company dedicated to developing innovative therapies for kidney-related disorders, particularly those affecting patients with chronic kidney disease.Tricida, Inc. specializes in biopharmaceuticals aimed at treating kidney disorders. Founded in 2013 and headquartered in San Francisco, US, the company has participated in 10 deals with its most recent funding round occurring on June 27, 2018. The latest investment was a VENTURE DEBT round totaling USD 25.00 mn, supported by Hercules Capital. The firm has raised a total of USD 42.00 mn. CEO Gerrit Klaerner leads the company, which has not undergone significant pivots or changes in business operations.Tricida focuses on developing therapies for kidney-related disorders, specifically targeting metabolic acidosis in patients with chronic kidney disease (CKD) on sodium-restricted diets. Their lead therapeutic candidate aims to restore acid-base balance, meeting critical medical needs in the CKD patient population. The products are primarily marketed in the US, where CKD prevalence is high, and are designed for nephrologists and healthcare providers managing these patients.Tricida's revenue model is centered around the commercialization of their lead therapeutic through direct sales to healthcare providers and partnerships with pharmaceutical distributors. They engage in supply agreements with hospitals and clinics to ensure accessibility of their treatment, reflecting a B2B model that collaborates with healthcare professionals to address patient needs in kidney disease management. The company's EBITDA for the most recent year, 2021, was USD -143.15 mn.Tricida plans to utilize its recent funding to advance the development of new products aimed at enhancing treatment options for kidney disorders. Following the successful IPO in June 2018, where they raised USD 222.30 mn by selling shares on the NASDAQ, the company is looking to expand their market presence. They aim to enter new geographic regions and explore further partnerships to enhance access to their therapies, thereby reinforcing their commitment to addressing unmet medical needs in the kidney disease sector.

## Funding rounds

- Series D, Nov 8, 2017, $58M — OrbiMed Advisors, Venrock, Vivo Capital, Wellington Management, Longitude Capital, Cormorant Asset Management, Sibling Capital Ventures, Limulus Venture Partners
- Series C, Jul 12, 2016, $24M — OrbiMed Advisors, Vivo Capital, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners
- Series B, Mar 4, 2015, $17M — OrbiMed Advisors, Sibling Capital Ventures, Limulus Venture Partners
- Series A, Sep 4, 2014, $10M — OrbiMed Advisors, Sibling Capital Ventures, Limulus Venture Partners

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C, Series D
- Sibling Capital Ventures (https://capitalatlas.ai/funds/sibling-capital-ventures) — Series A, Series B, Series C, Series D
- Limulus Venture Partners (https://capitalatlas.ai/funds/limulus-venture-partners) — Series A, Series B, Series C, Series D
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C, Series D
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series D
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D